Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.53 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.49 |
| ▸ | TERT | O14746 | 5/20 | 0.43 |
| ▸ | ELANE | P08246 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20581836 | 0.93 | ADORA3 (0.55) | ADORA3ACE2TERTKDM4EMEN1 | |
| SCHEMBL24345688 | 0.88 | ADORA3 (0.50) | ADORA3ACE2TERTKDM4EMEN1 | |
| SCHEMBL22076419 | 0.86 | ADORA3 (0.53) | ADORA3ACE2TERTKDM4EMEN1 | |
| SCHEMBL23117583 | 0.85 | ADORA3 (0.51) | ADORA3ACE2TERTKDM4EMEN1 | |
| SCHEMBL20581904 | 0.83 | ADORA3 (0.54) | ADORA3ACE2KDM4EMEN1ALDH1A1 | |
| SCHEMBL22076468 | 0.83 | ADORA3 (0.59) | ADORA3ACE2KDM4EMEN1ALDH1A1 | |
| SCHEMBL24344965 | 0.79 | KDM4E (0.50) | ADORA3ACE2KDM4EMEN1ALDH1A1 | |
| SCHEMBL23620821 | 0.78 | ADORA3 (0.51) | ADORA3ACE2KDM4EMEN1ALDH1A1 | |
| SCHEMBL20581913 | 0.78 | ADORA3 (0.53) | ADORA3ACE2KDM4EMEN1ALDH1A1 | |
| SCHEMBL23620819 | 0.78 | ADORA3 (0.43) | ADORA3ACE2TERTKDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210283157-A1 | ACYLATED ACTIVE AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF AUTOIMMUNE DISORDERS | SENDA BIOSCIENCES, INC. | 2021-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210283157-A1 | ACYLATED ACTIVE AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF AUTOIMMUNE DISORDERS | ENPP2, MBOAT7, AADAC | ADORA3 3697/4885ACE2 2472/4885TERT 3176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.